Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)
- Type: Workshop
- Track: N/A
- Presentations: 17
- Moderators:Yi-Long Wu
- Coordinates: 8/06/2022, 21:00 - 23:59, On-Demand
-
+
WS08.05 - Minimal Residual Disease (MRD) Negative: Potential for Cure in Resected Oncogene Driven NSCLC? Chinese Perspective
21:10 - 21:30 | Author(s): Jia-Tao Zhang
- Abstract
Loading... -
+
WS08.06 - Could MRD Change Our Clinical Practice? North American Perspective
21:30 - 21:50 | Author(s): Aadel Chaudhuri
- Abstract
Loading... -
+
WS08.07 - How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC
21:50 - 22:10 | Author(s): Jie Hu
- Abstract
Loading... -
+
WS08.09 - Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
22:30 - 22:40 | Author(s): Si-Yang Maggie Liu
- Abstract
Loading... -
+
WS08.10 - Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
22:40 - 22:50 | Author(s): Baohui Han
- Abstract
Loading... -
+
WS08.13 - Activity of aPD1-MSLN-CART Cells Against Metastatic Lung Cancer in a Phase 1 Trial
23:20 - 23:21 | Author(s): Lingjuan Chen
- Abstract
Loading... -
+
WS08.14 - Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC
23:21 - 23:22 | Author(s): Lin Wu
- Abstract
Loading... -
+
WS08.15 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
23:22 - 23:23 | Author(s): Jun Zhao
- Abstract
Loading... -
+
WS08.16 - The Increase of Blood Intratumor Heterogeneity is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC
23:23 - 23:24 | Author(s): Juan Zhou
- Abstract
Loading... -
+
WS08.17 - Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
23:24 - 23:25 | Author(s): Peng Song
- Abstract
Loading... -
+
WS08.18 - Discussant for Poster 1 - 5
23:25 - 23:40 | Author(s): Xiaorong Dong
- Abstract
Loading... -
+
WS08.24 - Discussant for Poster 6 - 10
23:35 - 23:50 | Author(s): Ming Fang Zhao
- Abstract
Loading... -
+
WS08.19 - Phase Il Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
23:40 - 23:41 | Author(s): Yao-Bin Lin
- Abstract
Loading... -
+
WS08.20 - Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
23:41 - 23:42 | Author(s): Yuan Li
- Abstract
Loading... -
+
WS08.21 - Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
23:42 - 23:43 | Author(s): Wen-Fang Tang
- Abstract
Loading... -
+
WS08.22 - Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)
23:43 - 23:44 | Author(s): Shi Yan
- Abstract
Loading... -
+
WS08.23 - Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
23:44 - 23:45 | Author(s): LinPing Gu
- Abstract
Loading...
-
+
EP05.02 - Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
- Type: E-Poster
- Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
- Presentations: 21
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP05.02-021 - An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC
Author(s): Yongchang Zhang- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 108
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.01-035 - Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC
Author(s): Guanghui Gao- Abstract
Loading... -
+
EP08.01-014 - Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303
Author(s): Caicun Zhou- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 171
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.02-064 - ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
Author(s): Qing Zhou- Abstract
Loading... -
+
EP08.02-171 - PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion‒Positive Metastatic Non‒Small Cell Lung Cancer (NSCLC)
Author(s): Rosario Garcia- Abstract
Loading...
-
+
EP16.01 - Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- Type: E-Poster
- Track: Tumor Biology and Biomarkers - Immune Biology & Immunotherapy
- Presentations: 31
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP16.01-005 - Cilia-related mRNA Profile Predicts Clinical Response to PD-1 Blockade in Lung Adenocarcinoma
Author(s): Guanghui Gao- Abstract
Loading...
-
+
ES05 - Oncogenic Alterations and Beyond - Novel Treatments
- Type: Education Session
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 9
- Moderators:Caicun Zhou
- Coordinates: 8/07/2022, 12:00 - 13:00, Hall C2
-
+
ES05.01 - Session Introduction
12:00 - 12:01 | Author(s): Caicun Zhou
- Abstract
Loading... -
+
Session Moderator
12:00 - 12:00 | Author(s): Caicun Zhou
- Abstract
Loading... -
+
Session Moderator
12:00 - 12:00 | Author(s): Maximilian Johannes Hochmair
- Abstract
Loading... -
+
ES05.02 - Session Introduction
12:01 - 12:02 | Author(s): Maximilian Johannes Hochmair
- Abstract
Loading... -
+
ES05.03 - Targeting Rarer Events in Known Targets: EGFR Exon20 (EGFR, HER2)
12:02 - 12:14 | Author(s): Giannis Mountzios
- Abstract
Loading... -
+
ES05.04 - All You Need to Know About KRAS
12:14 - 12:26 | Author(s): Odd Terje Brustugun
- Abstract
Loading... -
+
ES05.05 - Antibody-Drug Conjugates - Where We Stand Today?
12:26 - 12:38 | Author(s): Bob T. Li
- Abstract
Loading... -
+
ES05.06 - HRD/DDR in Lung Cancer: Role and Therapeutic Implications
12:38 - 12:50 | Author(s): Lauren Averett Byers
- Abstract
Loading... -
+
ES05.07 - Live Q&A
12:50 - 13:00
- Abstract
Loading...
-
+
PL03 - Plenary 3: Presidential Symposium - Top Rated Abstracts (Live Streamed Session)
- Type: Plenary
- Track: N/A
- Presentations: 17
- Moderators:Heather Wakelee
- Coordinates: 8/08/2022, 08:30 - 10:20, Hall C1
-
+
PL03.09 - IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
Author(s): Heather Wakelee- Abstract
Loading...